Cambridge Cognition Holdings PLC Automated quality assurance for clinical trials (0261R)

TIDMCOG

RNS Number : 0261R

Cambridge Cognition Holdings PLC

24 October 2023

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

Launch of automated quality assurance for clinical trials

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the launch today of AQUA, the Company's automated quality assurance solution for central nervous system ("CNS") clinical trials that is powered by the Company's innovative Winterlight speech and language platform. This is the first such solution available in the market. The Company has already secured one customer for AQUA.

Cambridge Cognition believes there is considerable potential for AQUA. Based on independent market research commissioned by the Company, the market opportunity for automated quality assurance for CNS clinical trials measuring cognition alone is estimated to be GBP16m per annum within five years. Cambridge Cognition also believes there could be further opportunities for use of the technology in other therapeutic areas and in healthcare applications.

Quality assurance is an essential requirement for clinical trials as set out under 'Good Clinical Practice' guidelines. CNS clinical trials, for example for Alzheimer's disease or Schizophrenia, can rely on a clinician asking a patient questions and manually scoring the answer. In later stage, large clinical trials, quality assurance is critical as poor quality clinical consultations could change the result of the trial. Currently, expert clinicians usually listen to a proportion of patient consultations for later stage clinical trials to identify and report mistakes. Those reviews can be slow and expensive.

AQUA was developed by the Company using advanced voice technology developed by Winterlight to conduct quality assurance more quickly, economically and accurately. AQUA can be used to assess every single patient consultation and provide a structured report to the pharmaceutical company within hours, not days or weeks. The product is available in nine languages and is available for several widely-used CNS clinical instruments and adaptable for almost all. AQUA can also confirm that it is the same patient in each subsequent consultation.

With AQUA, pharmaceutical companies can be more confident that the data from their clinical trials is accurate. They can address problems, such as off-script questioning or inaccurate scoring, with a particular clinical trial site within hours. Then subsequently, they have reports from every single patient consultation as evidence of appropriate quality adherence for regulators for a new drug application.

The Company has conducted its own trial comparing non-experts using AQUA with expert clinicians, showing that there was a high degree of correlation. Using these results, the Company has already secured a lead customer for AQUA and the solution will be used for the first time in a phase II clinical trial for Alzheimer's disease that is starting later in 2023.

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"AQUA is an entirely new solution for the clinical trials market providing a level of quality assurance that was not possible before, from a cost or time perspective, with traditional reviews by medical experts. We acquired Winterlight Labs intending to commercialise their innovative verbal clinical assessments and, by launching AQUA, we have achieved the first of our product goals. We are also really pleased to have already won a client for AQUA as we expect this will provide us with an excellent case study for future sales. "

For further information, contact:

 
Cambridge Cognition Holdings Plc              Tel: 012 2381 0700 
 Matthew Stork, Chief Executive Officer        press@camcog.com 
 Stephen Symonds, Chief Financial Officer 
Panmure Gordon (UK) Limited (NOMAD and Joint  Tel: 020 7886 2968 
 Broker)                                       (Corporate Finance) 
 Freddy Crossley / Emma Earl                   (Corporate Broking) 
 Rupert Dearden 
Dowgate Capital Limited (Joint Broker)        Tel: 020 3903 7715 
 David Poutney / James Serjeant 
IFC Advisory Ltd (Financial PR and IR)        Tel: 020 3934 6630 
 Tim Metcalfe / Graham Herring / Zach Cohen

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBIBDGDBDDGXX

(END) Dow Jones Newswires

October 24, 2023 02:05 ET (06:05 GMT)

Cambridge Cognition (AQSE:COG.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024